Please try another search
For the three months ended 31 March 2022, MorphoSys AG revenues decreased 12% to EUR41.5M. Net loss increased from EUR41.6M to EUR122.7M. Revenues reflect Europe and Asia segment decrease of 96% to EUR700K. Higher net loss reflects Research and Development - Balancing val increase from EUR21.6M to EUR49.9M (expense), Finance Expenses - Balancing value increase of 68% to EUR59.4M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 41.47 | 52.94 | 41.24 | 38.23 |
Gross Profit | 33.57 | 43.42 | 33.76 | 28.1 |
Operating Income | -70.39 | -323.62 | -81.34 | -70.94 |
Net Income | -122.65 | -380.97 | -112.77 | 20.89 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 2457.36 | 2556.25 | 2883.94 | 1577.41 |
Total Liabilities | 2315.62 | 2311.38 | 2286.69 | 976.01 |
Total Equity | 141.74 | 244.88 | 597.25 | 601.41 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -143.81 | -481.45 | -323.96 | -131.59 |
Cash From Investing Activities | 115.19 | -831.01 | -850.08 | 292.73 |
Cash From Financing Activities | 13.77 | 1322.92 | 1317 | 27.86 |
Net Change in Cash | -14.37 | 13.45 | 139.97 | 187.54 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review